Compare Dolby Laboratories, Inc. (DLB) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Novavax Inc — how do they compare? Dolby Laboratories, Inc. trades at $60.9 (market cap $5.75B), while Novavax Inc trades at $7.94 (market cap $1.31B). The key difference: Dolby Laboratories, Inc. is far larger — about 4.4× Novavax Inc's market cap, and Dolby Laboratories, Inc. pays a 2.35% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| DLB | NVAX | |
|---|---|---|
Market Cap | $5.75B | $1.31B |
Sector | Industrials | Health |
52-Week High | $75.62 | $11.19 |
52-Week Low | $48.51 | $6.22 |
Enterprise Value | $5.12B | $889.30M |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
